Download PDF
Homœopathic Links 2014; 27(2): 63
DOI: 10.1055/s-0034-1368430
EDITORIAL
Sonntag Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart · New York

EDITORIAL

Harry van der Zee
Further Information

Publication History

Publication Date:
05 June 2014 (online)

   Permissions and Reprints

In a recent publication “Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma” (Nature 2014)[1], the authors concluded that their “findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a ‘drug holiday’ and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.”